Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1–Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial

Martin Reck, Fabrice Barlesi, James Chih Hsin Yang, Virginie Westeel, Enriqueta Felip, Mustafa Özgüroğlu, Manuel Cobo Dols, Richard Sullivan, Dariusz M. Kowalski, Zoran Andric, Dae Ho Lee, Ahmet Sezer, Ping Hu, Xiao Zhe Wang, Anja von Heydebreck, Natalia Jacob, Keyvan Tadjalli Mehr, Keunchil Park

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1–Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences